RENEURON GRP

 

RENEURON GRP (RENE.L, LSE, LSE:RENE)

RENE Share PerformanceMore

52 week high4.7000 22/04/15
52 week low2.7500 16/06/14
52 week change 0.8250 (24.09%)
4 week volume53,298,206 01/04/15

Media for (RENE)

Presenter: Michael Hunt, CEO
04/02/2015

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Second Price Monitoring Extn

RNS Number: 0450L ReNeuron Group plc 22 April 2015 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The closing auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this security would still have executed more than a pre-determi...

Price Monitoring Extension

RNS Number: 0434L ReNeuron Group plc 22 April 2015 Price Monitoring Extension Today's closing auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security's closing auction call bef...

ReNeuron clinical trial results

ReNeuron Group, a leading UK-based stem cell therapy company, has provided a further and final update on the PISCES...

Long Term Clinical Data from PISCES Stroke Trial

RNS Number: 5695K ReNeuron Group plc 17 April 2015 17 April 2015 AIM: RENE Long term data from first clinical trial of ReNeuron's stem cell therapy for stroke to be presented at leading stroke conference Long term data continue to show good safety profile and evidence of sustained improvements in neurological status and limb function Guildford, UK, 17 Ap...

ReNeuron seeks to begin Phase 1/11 trials for hRPC

ReNeuron Group has filed an Investigational New Drug (IND) application with the US FDA to commence a Phase I/II clin...

IND in the US

RNS Number: 9658J ReNeuron Group plc 13 April 2015 13 April 2015 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") ReNeuron files application to commence Phase I/II clinical trial in the US with its stem cell therapy candidate for the blindness-causing disease, retinitis pigmentosa Guildford, UK, 13 April 2015: ReNeuron Group plc (AIM: RENE), ...

Reconfigures Board and Strengthens Executive Team

RNS Number: 0897J ReNeuron Group plc 01 April 2015 1 April 2015 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") ReNeuron reconfigures Board and further strengthens executive management for next phase of development Guildford, UK, 1 April 2015: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, today ...

Should You Follow Neil Woodford And Buy GlaxoSmithKline plc, AstraZeneca plc, Circassia Pharmaceuticals PLC, Oxford Pharmascience Group Plc And ReNeuron Group Plc?

Neil Woodford has been an investor in the pharmaceuticals industry for most of his long career. In a recent blog, the ace f...

Fundamental DataMore

EPS-0.5
Dividend yield0 %

Equity Research (RENE)

edison investment research
ReNeuron Group plc
23/04/2015
ReNeuron presented two-year follow-up data from the PISCES study in disabled stroke patients, which confirm the potential for long-term benefits from treatment with its CTX neural stem cells....
edison investment research
ReNeuron Group plc
28/11/2014
ReNeuron is facing a potentially transformational year in 2015, with key clinical data and relocation to a new cell manufacturing/research facility. Its allogeneic, CTX neural stem cell product is...
edison investment research
ReNeuron Group plc
29/09/2014
ReNeuron operates off solid fundamentals as it seeks to advance its novel stem cell technology. Last year’s £25.3m fundraise coupled with a £7.8m grant from the Welsh government to build a new...

Users' HoldingsMore

Users who hold RENEURON GRP also hold..
ROYAL BK OF SCOTLD GRP,THE13%
BP13%
BARCLAYS12%
LLOYDS BANKING GRP12%
GLAXOSMITHKLINE11%

Codes & Symbols

ISINGB00B0DZML60
SymbolsRENE, LSE:RENE, RENE.L, RENE:LN, LON:RENE, XLON:RENE